GI-Cell opens the way for autoimmune disease treatments by obtaining patent for regulatory T cell large-scale culture technology 

GI-Cell, a South Korea-based company specializing in immune cell therapy, announced on November 29 that it obtained a domestic patent for a large-scale culture technology of regulatory T cells for the treatment of autoimmune diseases. With this patent, GI-Cell is expected to become a leader in the autoimmune disease space in the country.

Regulatory T cells maintain immune system homeostasis through immunosuppression regulation. Regulatory T cells have been in the spotlight as a therapeutic agent for diseases caused by imbalance of the immune system, such as autoimmune diseases. However, the proportion of regulatory T cells among the total T cells is only about 2-3%, making it difficult to separate and culture cells. It is also difficult to develop therapeutic agents because the characteristic properties of regulatory T cells are easily lost during the culturing process. However, GI-Cell succeeded in maintaining highly functional regulatory T cells through its unique and differentiated culture technology with improved productivity.

Link: http://www.thebell.co.kr/free/Content/ArticleView.asp?key=202111291753495280109296&svccode=06